Skip to main content

Articles

Page 3 of 33

  1. Dementia is defined as a cognitive decline that affects functional status. Longitudinal ageing surveys often lack a clinical diagnosis of dementia though measure cognition and daily function over time. We used...

    Authors: Amin Gharbi-Meliani, François Husson, Henri Vandendriessche, Eleonore Bayen, Kristine Yaffe, Anne-Catherine Bachoud-Lévi and Laurent Cleret de Langavant
    Citation: Alzheimer's Research & Therapy 2023 15:209
  2. To estimate the perceived value of additional testing with amyloid-PET in Euros in healthy participants acting as analogue patients with mild cognitive impairment (MCI).

    Authors: I. S. van Maurik, E. D. Bakker, A. A. J. M. van Unnik, H. M. Broulikova, M. D. Zwan, E. van de Giessen, J. Berkhof, F. H. Bouwman, J. E. Bosmans and W. M. van der Flier
    Citation: Alzheimer's Research & Therapy 2023 15:208
  3. Previous studies demonstrated increases in diagnostic confidence and change in patient management after amyloid-PET. However, studies investigating longitudinal outcomes over an extended period of time are lim...

    Authors: Lyduine E. Collij, Gill Farrar, Marissa Zwan, Elsmarieke van de Giessen, Rik Ossenkoppele, Frederik Barkhof, Annemieke J. M. Rozemuller, Yolande A. L. Pijnenburg, Wiesje M. van der Flier and Femke Bouwman
    Citation: Alzheimer's Research & Therapy 2023 15:207
  4. High gait variability is associated with neurodegeneration and cognitive impairments and is predictive of cognitive impairment and dementia. The objective of this study was to identify cortical or subcortical ...

    Authors: Seonjeong Byun, Hyang Jun Lee, Jun Sung Kim, Euna Choi, Subin Lee, Tae Hui Kim, Jae Hyoung Kim, Ji Won Han and Ki Woong Kim
    Citation: Alzheimer's Research & Therapy 2023 15:206
  5. Cognitive complaints are often regarded as an early sign of Alzheimer’s disease (AD) but may also occur in several other conditions and contexts. This study examines the correlates of cognitive complaint traje...

    Authors: Federica Cacciamani, Ariane Bercu, Vincent Bouteloup, Leslie Grasset, Vincent Planche, Geneviève Chêne and Carole Dufouil
    Citation: Alzheimer's Research & Therapy 2023 15:205
  6. There are increasing reports on the cognitive and emotional benefits of positive reminiscence therapy in older people. The objective of this study is to assess the differential improvement of the quality of li...

    Authors: Alba Villasán Rueda, Antonio Sánchez Cabaco, Manuel Alejandro Mejía-Ramírez, Rosa Marina Afonso and Eduardo Castillo-Riedel
    Citation: Alzheimer's Research & Therapy 2023 15:204
  7. Participant retention is a key factor that affects clinical trial integrity. Trial protocols estimate attrition as a function of sample size calculations. Alzheimer’s disease (AD) is an area of active treatmen...

    Authors: Marina Ritchie, Daniel L. Gillen and Joshua D. Grill
    Citation: Alzheimer's Research & Therapy 2023 15:203
  8. Identification of patients with idiopathic normal pressure hydrocephalus (iNPH) in a collective with suspected neurodegenerative disease is essential. This study aimed to determine the metabolic spatial covari...

    Authors: Alexander Rau, Nils Schröter, Ganna Blazhenets, Christoph Maurer, Horst Urbach, Philipp T. Meyer and Lars Frings
    Citation: Alzheimer's Research & Therapy 2023 15:202
  9. Progression of Alzheimer’s disease leads to synapse loss, neural network dysfunction and cognitive failure. Accumulation of protein aggregates and brain immune activation have triggering roles in synaptic fail...

    Authors: Austin Stoner, Li Fu, LaShae Nicholson, Chao Zheng, Takuya Toyonaga, Joshua Spurrier, Will Laird, Zhengxin Cai and Stephen M. Strittmatter
    Citation: Alzheimer's Research & Therapy 2023 15:201
  10. Health-related quality of life (HR-QoL) is an important outcome for patients and crucial for demonstrating the value of new treatments. Health utility estimates in subjective cognitive decline (SCD) and mild c...

    Authors: Sandar Aye, Vincent Bouteloup, Ashley Tate, Anders Wimo, Ron Handels, Delphine Jean, Bengt Winblad and Linus Jönsson
    Citation: Alzheimer's Research & Therapy 2023 15:200
  11. Understanding the pathological characteristics of various mild cognitive impairment (MCI) subtypes is crucial for the differential diagnosis of dementia. The purpose of this study was to feature divergent symp...

    Authors: Chao Du, Mingxi Dang, Kewei Chen, Yaojing Chen and Zhanjun Zhang
    Citation: Alzheimer's Research & Therapy 2023 15:199
  12. Subjective cognitive complaints (SCC) have been mostly studied in the context of Alzheimer’s disease in memory clinic settings. The potential of combining SCC with genetic information and blood biomarkers of ...

    Authors: Laura Perna, Hannah Stocker, Lena Burow, Léon Beyer, Kira Trares, Carolin Kurz, Selim Gürsel, Bernd Holleczek, Maia Tatò, Konrad Beyreuther, Ute Mons, Klaus Gerwert, Robert Perneczky, Ben Schöttker and Hermann Brenner
    Citation: Alzheimer's Research & Therapy 2023 15:198
  13. Cholesterol plays important roles in β-amyloid (Aβ) metabolism and atherosclerosis. However, the relationships of plasma cholesterol levels with Aβ and cerebral small vessel disease (CSVD) burdens are not full...

    Authors: Sung Hoon Kang, Heejin Yoo, Bo Kyoung Cheon, Yu Hyun Park, Soo-Jong Kim, Hongki Ham, Hyemin Jang, Hee Jin Kim, Kyungmi Oh, Seong-Beom Koh, Duk L. Na, Jun Pyo Kim and Sang Won Seo
    Citation: Alzheimer's Research & Therapy 2023 15:197
  14. Genomic study of cognition decline while considering baseline cognition and lifestyle behaviors is scarce. We aimed to evaluate the impact of a polygenic score for general cognition on cognition decline rate, ...

    Authors: Tingting Liu, Changwei Li, Ruiyuan Zhang, Eugenia Flores Millender, Hongyu Miao, Michael Ormsbee, Jinzhen Guo, Adrianna Westbrook, Yang Pan, Jing Wang and Tanika N. Kelly
    Citation: Alzheimer's Research & Therapy 2023 15:196
  15. The Alzheimer’s disease (AD) risk gene ABCA7 has suggested functions in lipid metabolism and the immune system. Rare premature termination codon (PTC) mutations and an expansion of a variable number of tandem rep...

    Authors: Lena Duchateau, Fahri Küҫükali, Arne De Roeck, Mandy M. J. Wittens, Joke Temmerman, Ilse Weets, Maarten Timmers, Sebastiaan Engelborghs, Maria Bjerke and Kristel Sleegers
    Citation: Alzheimer's Research & Therapy 2023 15:195
  16. Inflammation plays a key role in the development of dementia, but its link to early biomarkers, particularly those in plasma or neuroimaging, remains elusive. This study aimed to investigate the association be...

    Authors: Amber Yaqub, Samer R. Khan, Meike W. Vernooij, P. Martin van Hagen, Robin P. Peeters, M. Arfan Ikram, Layal Chaker and Virgil A. S. H. Dalm
    Citation: Alzheimer's Research & Therapy 2023 15:194
  17. The pathological process of Alzheimer’s disease (AD) typically takes decades from onset to clinical symptoms. Early brain changes in AD include MRI-measurable features such as altered functional connectivity (...

    Authors: Yujian Diao, Bernard Lanz and Ileana Ozana Jelescu
    Citation: Alzheimer's Research & Therapy 2023 15:193
  18. We have proposed that cognitive resilience (CR) counteracts brain damage from Alzheimer’s disease (AD) or AD-related dementias such that older individuals who harbor neurodegenerative disease burden sufficient...

    Authors: Thanaphong Phongpreecha, Dana Godrich, Eloise Berson, Camilo Espinosa, Yeasul Kim, Brenna Cholerton, Alan L. Chang, Samson Mataraso, Syed A. Bukhari, Amalia Perna, Koya Yakabi, Kathleen S. Montine, Kathleen L. Poston, Elizabeth Mormino, Lon White, Gary Beecham…
    Citation: Alzheimer's Research & Therapy 2023 15:192
  19. Alzheimer’s disease is a prevalent disease with a heavy global burden. Proteomics is the systematic study of proteins and peptides to provide comprehensive descriptions. Aiming to obtain a more accurate and co...

    Authors: Yuye Wang, Yu Sun, Yu Wang, Shuhong Jia, Yanan Qiao, Zhi Zhou, Wen Shao, Xiangfei Zhang, Jing Guo, Bin Zhang, Xiaoqian Niu, Yi Wang and Dantao Peng
    Citation: Alzheimer's Research & Therapy 2023 15:191
  20. There is a tremendous need for identifying reliable blood-based biomarkers for Alzheimer’s disease (AD) that are tied to the biological ATN (amyloid, tau and neurodegeneration) framework as well as clinical as...

    Authors: Zhengshi Yang, Karthik Sreenivasan, Erin N. Toledano Strom, Amanda M. Leisgang Osse, Lorenzo Gabriel Pasia, Celica Glenn Cosme, Maya Rae N. Mugosa, Emma Léa Chevalier, Aaron Ritter, Justin B. Miller, Dietmar Cordes, Jeffrey L. Cummings and Jefferson W. Kinney
    Citation: Alzheimer's Research & Therapy 2023 15:190
  21. The mismatch between the limited availability versus the high demand of participants who are in the pre-dementia phase of Alzheimer’s disease (AD) is a bottleneck for clinical studies in AD. Nevertheless, pote...

    Authors: Ilse Bader, Ilona Bader, Isadora Lopes Alves, David Vállez García, Bruno Vellas, Bruno Dubois, Mercè Boada, Marta Marquié, Daniele Altomare, Philip Scheltens, Rik Vandenberghe, Bernard Hanseeuw, Michael Schöll, Giovanni B. Frisoni, Frank Jessen, Agneta Nordberg…
    Citation: Alzheimer's Research & Therapy 2023 15:189
  22. The over-activation of adenosine A2A receptors (A2AR) is closely implicated in cognitive impairments of Alzheimer's disease (AD). Growing evidence shows that A2AR blockade possesses neuroprotective effects on AD....

    Authors: Qi Ji, Yang Yang, Yun Xiong, Ying-Jie Zhang, Jun Jiang, Li-Ping Zhou, Xiao-Hui Du, Chun-Xiang Wang and Zhi-Ru Zhu
    Citation: Alzheimer's Research & Therapy 2023 15:187
  23. Synapse loss is an early event that precedes neuronal death and symptom onset and is considered the best neuropathological correlate of cognitive decline in Alzheimer’s disease (AD). Vesicle-associated membran...

    Authors: Julie Goossens, Alba Cervantes González, Nele Dewit, Laia Lidón, Juan Fortea, Daniel Alcolea, Alberto Lleó, Olivia Belbin and Eugeen Vanmechelen
    Citation: Alzheimer's Research & Therapy 2023 15:186
  24. Alzheimer's disease (AD) is a neurodegenerative disease and the main cause for dementia. The irreversible neurodegeneration leads to a gradual loss of brain function characterized predominantly by memory loss....

    Authors: Xiaozhu Liu, Samuel Halvorsen, Nathan Blanke, Margaret Downs, Thor D. Stein, Irving J. Bigio, Joseph Zaia and Yanhang Zhang
    Citation: Alzheimer's Research & Therapy 2023 15:185
  25. In MAPT (Multidomain Alzheimer Preventive Trial), a cognitive effect of multidomain intervention (MI) was showed in non-demented subjects with positive amyloid PET. However, screening eligible patients for mul...

    Authors: Julien Delrieu, Bruno Vellas, Sophie Guyonnet, Christelle Cantet, Vitaliy Ovod, Yan Li, James Bollinger, Randall Bateman and Sandrine Andrieu
    Citation: Alzheimer's Research & Therapy 2023 15:183
  26. To enable successful inclusion of electroencephalography (EEG) outcome measures in Alzheimer’s disease (AD) clinical trials, we retrospectively mapped the progression of resting-state EEG measures over time in...

    Authors: Elliz P. Scheijbeler, Willem de Haan, Cornelis J. Stam, Jos W. R. Twisk and Alida A. Gouw
    Citation: Alzheimer's Research & Therapy 2023 15:182
  27. APOE genotype is the greatest genetic risk factor for sporadic Alzheimer’s disease (AD). APOE4 increases AD risk up to 12-fold compared to APOE3, an effect that is greater in females. Evidence suggests that one-w...

    Authors: Deebika Balu, Ana C. Valencia-Olvera, Austin Nguyen, Mehul Patnam, Jason York, Francesco Peri, Frank Neumann, Mary Jo LaDu and Leon M. Tai
    Citation: Alzheimer's Research & Therapy 2023 15:181
  28. Alzheimer’s disease involves accumulating amyloid (A) and tau (T) pathology, and progressive neurodegeneration (N), leading to the development of the AD clinical syndrome. While several markers of N have been ...

    Authors: Rigina L. Gallagher, Rebecca Langhough Koscik, Jason F. Moody, Nicholas M. Vogt, Nagesh Adluru, Steven R. Kecskemeti, Carol A. Van Hulle, Nathaniel A. Chin, Sanjay Asthana, Gwendlyn Kollmorgen, Ivonne Suridjan, Cynthia M. Carlsson, Sterling C. Johnson, Douglas C. Dean III, Henrik Zetterberg, Kaj Blennow…
    Citation: Alzheimer's Research & Therapy 2023 15:180
  29. Current treatments for Alzheimer’s disease (AD) have largely failed to yield significant therapeutic benefits. Novel approaches are desperately needed to help address this immense public health issue. Data sug...

    Authors: Nancy R. Stallings, Melissa A. O’Neal, Jie Hu, Zhong-Jian Shen and James S. Malter
    Citation: Alzheimer's Research & Therapy 2023 15:179
  30. The effect of amyloid-β (Aβ) on cognitive impairment in patients with small subcortical infarction remains controversial, although a growing body of evidence shows a substantial overlap between Alzheimer’s dis...

    Authors: Sung Hoon Kang, Minwoong Kang, Jung Hoon Han, Eun Seong Lee, Keon-Joo Lee, Su Jin Chung, Sang-Il Suh, Seong-Beom Koh, Jae Seon Eo, Chi Kyung Kim and Kyungmi Oh
    Citation: Alzheimer's Research & Therapy 2023 15:178
  31. Authors: Patricia Diaz‑Galvan, Giulia Lorenzon, Rosaleena Mohanty, Gustav Mårtensson, Enrica Cavedo, Simone Lista, Andrea Vergallo, Kejal Kantarci, Harald Hampel, Bruno Dubois, Michel J. Grothe, Daniel Ferreira and Eric Westman
    Citation: Alzheimer's Research & Therapy 2023 15:177

    The original article was published in Alzheimer's Research & Therapy 2023 15:117

  32. Mild cognitive impairment (MCI) is often considered an early stage of dementia, with estimated rates of progression to dementia up to 80–90% after approximately 6 years from the initial diagnosis. Diagnosis of...

    Authors: Kevin Blanco, Stefanny Salcidua, Paulina Orellana, Tania Sauma-Pérez, Tomás León, Lorena Cecilia López Steinmetz, Agustín Ibañez, Claudia Duran-Aniotz and Rolando de la Cruz
    Citation: Alzheimer's Research & Therapy 2023 15:176
  33. Development of in vivo biomarkers has shifted the diagnosis of Alzheimer’s disease (AD) from the later dementia stages of disease towards the earlier stages and has introduced the potential for pre-symptomatic...

    Authors: Bruno Dubois, Christine A. F. von Arnim, Nerida Burnie, Sasha Bozeat and Jeffrey Cummings
    Citation: Alzheimer's Research & Therapy 2023 15:175
  34. Soluble amyloid-beta oligomers (Aβo) begin to accumulate in the human brain one to two decades before a clinical diagnosis of Alzheimer’s disease (AD). The literature supports that soluble Aβo are implicated i...

    Authors: Audrey Hector, Chloé Provost, Benoît Delignat-Lavaud, Khadija Bouamira, Chahinez-Anissa Menaouar, Valérie Mongrain and Jonathan Brouillette
    Citation: Alzheimer's Research & Therapy 2023 15:174
  35. It is unknown if fluid biomarkers reflective of brain pathologies are useful in detecting and following a neurodegenerative process in individuals exposed to repetitive head impacts. This study explores the re...

    Authors: Charles Bernick, Guogen Shan, Aaron Ritter, Nicholas J. Ashton, Kaj Blennow, Juan Lantero-Rodriguez, Anniina Snellman and Henrik Zetterberg
    Citation: Alzheimer's Research & Therapy 2023 15:173
  36. Compared to standard neuro-diagnostic techniques, retinal biomarkers provide a probable low-cost and non-invasive alternative for early Alzheimer’s disease (AD) risk screening. We have previously quantified th...

    Authors: Edmund Arthur, Swetha Ravichandran, Peter J. Snyder, Jessica Alber, Jennifer Strenger, Ava K. Bittner, Rima Khankan, Stephanie L. Adams, Nicole M. Putnam, Karin R. Lypka, Juan A. Piantino and Stuart Sinoff
    Citation: Alzheimer's Research & Therapy 2023 15:172
  37. Alterations in mitochondrial DNA (mtDNA) levels have been observed in Alzheimer’s disease and are an area of research that shows promise as a useful biomarker. It is well known that not only are the mitochondr...

    Authors: Isabelle K. Gorham, Robert C. Barber, Harlan P. Jones and Nicole R. Phillips
    Citation: Alzheimer's Research & Therapy 2023 15:171
  38. The glymphatic system is a crucial component in preserving brain homeostasis by facilitating waste clearance from the central nervous system (CNS). Aquaporin-4 (AQP4) water channels facilitate the continuous i...

    Authors: Pablo Mohaupt, Jérôme Vialaret, Christophe Hirtz and Sylvain Lehmann
    Citation: Alzheimer's Research & Therapy 2023 15:170
  39. The first predominant clinical symptoms of dementia with Lewy bodies (DLB) are highly variable; however, the prognosis based on initial predominant symptoms remains poorly understood.

    Authors: Clément Aveneau, David Wallon, Bertrand Degos, Alexandre Obadia, Claire Hourregue, Sarah Benisty, Béatrice Garcin, Julien Dumurgier and Claire Paquet
    Citation: Alzheimer's Research & Therapy 2023 15:169
  40. Tauopathies are a group of neurodegenerative disorders characterized by the aggregation of the microtubule-associated protein tau. Aggregates of misfolded tau protein are believed to be implicated in neuronal ...

    Authors: Jeffrey L. Cummings, M. Isabel Gonzalez, Martyn C. Pritchard, Patrick C. May, Leticia M. Toledo-Sherman and Glenn A. Harris
    Citation: Alzheimer's Research & Therapy 2023 15:168
  41. Prevalence of overall cognitive impairment based on each participant’s performance across a neuropsychological battery is challenging; consequently, we define and validate a dichotomous cognitive impairment/no...

    Authors: Megan E. O’Connell, Helena Kadlec, Lauren E. Griffith, Christina Wolfson, Geva Maimon, Vanessa Taler, Susan Kirkland and Parminder Raina
    Citation: Alzheimer's Research & Therapy 2023 15:167
  42. Exposure to repetitive head impacts (RHI) in American football players can lead to cognitive impairment and dementia due to neurodegenerative disease, particularly chronic traumatic encephalopathy (CTE). The p...

    Authors: Robert A. Stern, Diana Trujillo-Rodriguez, Yorghos Tripodis, Surya V. Pulukuri, Michael L. Alosco, Charles H. Adler, Laura J. Balcer, Charles Bernick, Zachary Baucom, Kenneth L. Marek, Michael D. McClean, Keith A. Johnson, Ann C. McKee, Thor D. Stein, Jesse Mez, Joseph N. Palmisano…
    Citation: Alzheimer's Research & Therapy 2023 15:166
  43. There has been increasing interest in cortical microstructure as a complementary and earlier measure of neurodegeneration than macrostructural atrophy, but few papers have related cortical diffusion imaging to...

    Authors: Mario Torso, Gerard R. Ridgway, Michele Valotti, Ian Hardingham and Steven A. Chance
    Citation: Alzheimer's Research & Therapy 2023 15:165
  44. Hyperhomocysteinemia (HHcy) has been linked to development of Alzheimer’s disease (AD) neuropathologically characterized by the accumulation of amyloid β (Aβ). Microglia (MG) play a crucial role in uptake of A...

    Authors: Xianwei Wang, Lu Liu, Xiaohua Jiang, Jason Saredy, Hang Xi, Ramon Cueto, Danni Sigler, Mohsin Khan, Sheng Wu, Yong Ji, Nathaniel W. Snyder, Wenhui Hu, Xiaofeng Yang and Hong Wang
    Citation: Alzheimer's Research & Therapy 2023 15:164
  45. The arrival of new disease-modifying treatments for Alzheimer’s disease (AD) requires the identification of subjects at risk in a simple, inexpensive, and non-invasive way. With tools allowing an adequate scre...

    Authors: Francisco Martínez-Dubarbie, Armando Guerra-Ruiz, Sara López-García, Carmen Lage, Marta Fernández-Matarrubia, Jon Infante, Ana Pozueta-Cantudo, María García-Martínez, Andrea Corrales-Pardo, María Bravo, Marcos López-Hoyos, Juan Irure-Ventura, Pascual Sánchez-Juan, María Teresa García-Unzueta and Eloy Rodríguez-Rodríguez
    Citation: Alzheimer's Research & Therapy 2023 15:163
  46. Chronic stress and depression are potential risk factors for mild cognitive impairment and dementia, including Alzheimer disease. The aim was to investigate whether any such risk is additive.

    Authors: Johanna Wallensten, Gunnar Ljunggren, Anna Nager, Caroline Wachtler, Nenad Bogdanovic, Predrag Petrovic and Axel C. Carlsson
    Citation: Alzheimer's Research & Therapy 2023 15:161
  47. This article has been retracted. Please see the Retraction Notice for more detail: https://doi.org/10.1186/s13195-021-00769-9.

    Authors: Panchanan Maiti, Zackary Bowers, Ali Bourcier-Schultz, Jarod Morse and Gary L. Dunbar
    Citation: Alzheimer's Research & Therapy 2023 15:162